Murray responds to vaccine plan from Trump Administration that remains silent on crucial questions, including when it comes to researching, developing, reviewing, and manufacturing safe and effective vaccines
Murray: “This is one part of a complicated puzzle that is still missing far too many pieces.”
(Washington, D.C.) – Today, U.S. Senator Patty Murray (D-WA), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee, released the following statement in response to a vaccine distribution plan released by the Department of Health and Human Services and the Department of Defense. Senator Murray has repeatedly pressed the Trump Administration to develop and implement a comprehensive, end-to-end national vaccines plan, and laid out what such a plan should entail in a white paper.
“This is one part of a complicated puzzle that is still missing far too many pieces. I’m glad we’re finally starting to get some of the details on vaccine distribution that I have been pressing this Administration to provide for months. However, I’m concerned after reviewing this plan that the Administration is still silent on a lot of big challenges that lie ahead on vaccines, including when it comes research, development, review, and manufacturing, and that this plan says too little on addressing disparities.
“These are just a few of many crucial questions, yet the Departments’ announcement today does little to answer them.
“We simply can’t afford any mistakes or delays when it comes to ensuring a safe, effective, and trusted vaccine is manufactured at scale, and widely and equitably distributed and administered. That’s why I’m going to keep pushing for the kind of truly comprehensive, national plan that is long overdue.”
Senator Murray has frequently called for a comprehensive, end-to-end national vaccines plan. She put out a white paper earlier this year detailing exactly what such a plan should entail, and has emphasized these issues repeatedly at Senate hearings as well. She is continuing to push for Congress to include a requirement the Administration develop such a plan in any future COVID-19 package. She has also sent several letters to the Administration raising her concerns with the outstanding questions regarding its vaccine planning, including a letter warning against sidelining experts at the Centers for Disease Control and Prevention (CDC) and a letter asking the Food and Drug Administration (FDA) to issue official FDA guidance on the criteria for emergency authorization of COVID-19 vaccines.